Bio-Techne (Bio-Techne) DeferredTaxAndRevenue

: $28 Mil (As of Dec. 2023)

View and export this data going back to 1992. Start your Free Trial

Deferred Tax And Revenue represents the current portion of obligations, which is a liability that usually would have been paid but is now pas due.

Bio-Techne's current deferred tax and revenue for the quarter that ended in Dec. 2023 was $28 Mil.

Bio-Techne DeferredTaxAndRevenue Historical Data

The historical data trend for Bio-Techne's DeferredTaxAndRevenue can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Bio-Techne Annual Data

Trend

Jun14

Jun15

Jun16

Jun17

Jun18

Jun19

Jun20

Jun21

Jun22

Jun23

DeferredTaxAndRevenue

9.08

13.05

19.00

23.41

23.07

Bio-Techne Quarterly Data
	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
DeferredTaxAndRevenue																21.81	24.88	23.07	24.52	28.43

Bio-Techne DeferredTaxAndRevenue Related Terms

Thank you for viewing the detailed overview of Bio-Techne's DeferredTaxAndRevenue provided by GuruFocus.com. Please click on the following links to see related term pages.

Bio-Techne (Bio-Techne) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Bio-Techne Corp (NAS:TECH) » Definitions » DeferredTaxAndRevenue

Comparable Companies

Traded in Other Exchanges

TE1:Germany T1CH34:Brazil

Address

614 McKinley Place N.E., Minneapolis, MN, USA, 55413

Website

https://www.bio-techne.com

Based in Minnesota, Bio-Techne is a life sciences manufacturer supplying consumables and instruments for the pharma, biotech, academic, and diagnostic markets. The company reports in two segments, protein sciences (75% of revenue), and diagnostics and genomics (25%). The protein-focused segment makes equipment and associated consumables for protein characterization and analysis and sells antibodies for research and clinical purposes. In diagnostics, Bio-Techne provides controls and calibrators for diagnostic manufacturers and has a portfolio of diagnostic oncology assays. The United States accounts for about 55% of revenue, and the firm also has operations in EMEA (20% of sales), the U.K. (5%), and APAC (15%), with the rest of the world accounting for the remaining 5%.

Executives

Roeland Nusse	director	473 TENNESSEE, PALO ALTO CA 94306
William Geist	officer: PRESIDENT, PROTEIN SCIENCES	900 MIDDLESEX TURNPIKE, C/O QUANTERIX CORPORATION, BILLERICA MA 01821
Charles R. Kummeth	director, officer: Chief Executive Officer	425 MARTINGALE ROAD, SUITE 1000, SCHAUMBURG IL 60173-2213
Shane Bohnen	officer: SVP - General Counsel	614 MCKINLEY PLACE NE, MINNEAPOLIS MN 55413
Brenda S. Furlow	officer: SVP - General Counsel	614 MCKINLEY PLACE NE, MINNEAPOLIS MN 55413
John L Higgins	director	11119 NORTH TORREY PINES ROAD, SUITE 200, LA JOLLA CA 92037
Robert V Baumgartner	director	5775 WAYZATA BOULEVARD, SUITE 400, MINNEAPOLIS MN 55416
Kim Kelderman	officer: Pres. Diagnostics & Genom	614 MCKINLEY PLACE NE, MINNEAPOLIS MN 55413
Norman David Eansor	officer: SVP Biotech	8100 SOUTHPARK WAY, A-8, LITTLETON CO 80120
James Hippel	officer: Chief Financial Officer	614 MCKINLEY PLACE NE, MINNEAPOLIS MN 55413
Joseph D Keegan	director	C/O MOLECULAR DEVICES CORP, 1311 ORLEANS DRIVE, SUNNYVALE CA 94089
Alpna Seth	director	614 MCKINLEY PLACE NE, MINNEAPOLIS MN 55413
Julie L Bushman	director	185 SOUTH 84TH STREET, SUITE 200, MILWAUKEE WI 53214
Rupert Vessey	director	C/O CELGENE CORPORATION, 86 MORRIS AVENUE, SUMMIT NJ 07901
Randolph C Steer	director	614 MCKINLEY PLACE NE, MINNEAPOLIS MN 55413